NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: NaN
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$0.00 As of 07/10/2020 01:00 AM ET

+0.30 (1.20%)

Get New Synergy Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SGYP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGYP

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$0.00

This price target is based on 0 analysts offering 12 month price targets for Synergy Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Synergy Pharmaceuticals. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/15/2019

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/13/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/13/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/11/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/9/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/7/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/8/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/8/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
10/26/2018	Canaccord Genuity	Downgrade	Buy ➝ Hold		N/A	i
10/26/2018	BTIG Research	Downgrade	Buy ➝ Neutral		N/A	i Rating by Tim Chiang at BTIG Research
8/7/2018	HC Wainwright	Reiterated Rating	Buy	$7.00	High	i Rating by Ram Selvaraju at HC Wainwright
6/24/2018	Cantor Fitzgerald	Reiterated Rating	Hold		High	i
6/6/2018	HC Wainwright	Set Price Target	Buy	$7.00	High	i Rating by Ram Selvaraju at HC Wainwright
5/14/2018	BTIG Research	Set Price Target	Buy	$7.00	Low	i Rating by Tim Chiang at BTIG Research
5/13/2018	HC Wainwright	Set Price Target	Buy	$7.00	Low	i Rating by Ram Selvaraju at HC Wainwright
5/13/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Christopher Liu at Oppenheimer Holdings Inc.
5/7/2018	HC Wainwright	Set Price Target	Buy	$7.00	High	i Rating by Ram Selvaraju at HC Wainwright
3/22/2018	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Derek Archila at Oppenheimer Holdings Inc.
3/5/2018	HC Wainwright	Set Price Target	Buy	$7.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
3/1/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
2/1/2018	HC Wainwright	Reiterated Rating	Buy	$7.00	High	i Rating by Ram Selvaraju at HC Wainwright
2/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy		High	i Rating by W. Tanner at Cantor Fitzgerald
1/25/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	High	i Rating by W. Tanner at Cantor Fitzgerald
1/22/2018	Oppenheimer	Reiterated Rating	Hold		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
1/8/2018	HC Wainwright	Set Price Target	Buy	$7.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
1/5/2018	Oppenheimer	Reiterated Rating	Outperform ➝ Market Perform	$10.00	High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
1/5/2018	CIBC	Reiterated Rating	Outperform ➝ Market Perform		High	i
1/5/2018	Citigroup	Downgrade	Market Perform		High	i
1/4/2018	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
12/4/2017	HC Wainwright	Set Price Target	Buy	$7.00	High	i Rating by Ram Selvaraju at HC Wainwright
11/21/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	N/A	i Rating by W. Tanner at Cantor Fitzgerald
11/14/2017	BTIG Research	Reiterated Rating	Buy	$7.00	N/A	i
11/12/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
10/18/2017	HC Wainwright	Set Price Target	Buy	$8.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
10/11/2017	HC Wainwright	Set Price Target	Buy	$8.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
10/10/2017	Oppenheimer	Set Price Target	Buy	$6.00	N/A	i Rating by Derek Archila at Oppenheimer Holdings Inc.
9/25/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $8.00	Low	i Rating by Ram Selvaraju at HC Wainwright
9/13/2017	Citigroup	Reiterated Rating	Sell ➝ Sell	$3.20 ➝ $2.50	Medium	i
9/8/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Medium	i
9/8/2017	CIBC	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $6.00	Low	i
9/8/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$11.00	Medium	i Rating by W. Tanner at Cantor Fitzgerald
9/8/2017	Oppenheimer	Lower Price Target	Outperform	$9.00 ➝ $6.00	Medium	i Rating by Derek Archila at Oppenheimer Holdings Inc.
8/10/2017	Rodman & Renshaw	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $15.00	High	i
8/10/2017	HC Wainwright	Set Price Target	Buy	$15.00	High	i Rating by Ram Selvaraju at HC Wainwright
8/10/2017	Oppenheimer	Set Price Target	Buy	$9.00	High	i Rating by Derek Archila at Oppenheimer Holdings Inc.
8/10/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$11.00	High	i
7/31/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	Low	i Rating by John Newman at Canaccord Genuity
7/18/2017	Oppenheimer	Reiterated Rating	Outperform	$9.00	Low	i Rating by Derek Archila at Oppenheimer Holdings Inc.
7/10/2017	Canaccord Genuity	Reiterated Rating	Buy	$13.00	Low	i Rating by John Newman at Canaccord Genuity
6/28/2017	Citigroup	Reiterated Rating	Sell	$3.70	Low	i
6/27/2017	BTIG Research	Reiterated Rating	Buy	$11.00	High	i
6/14/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	Medium	i
6/12/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	Low	i Rating by Ram Selvaraju at HC Wainwright
6/9/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$11.00	Low	i
6/1/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$11.00	High	i
5/31/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low	i
5/23/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	High	i
5/19/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	Low	i Rating by Ram Selvaraju at HC Wainwright
5/19/2017	Canaccord Genuity	Reiterated Rating	Buy	$13.00	Low	i Rating by John Newman at Canaccord Genuity
5/10/2017	Oppenheimer	Set Price Target	Buy	$10.00 ➝ $9.00	Medium	i Rating by Derek Archila at Oppenheimer Holdings Inc.
4/22/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low	i
4/11/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low	i
4/6/2017	Citigroup	Downgrade	Neutral ➝ Sell		High	i
3/29/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	Low	i
3/28/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	Medium	i Rating by Ram Selvaraju at HC Wainwright
3/21/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low	i
3/16/2017	HC Wainwright	Set Price Target	Buy	$18.00	High	i Rating by Ram Selvaraju at HC Wainwright
3/3/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	N/A	i
3/2/2017	Oppenheimer	Set Price Target	Buy	$10.00	N/A	i Rating by Derek Archila at Oppenheimer Holdings Inc.
3/2/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
3/2/2017	Guggenheim	Reiterated Rating	Outperform	$10.00	N/A	i
1/31/2017	Oppenheimer	Reiterated Rating	Outperform	$10.00	N/A	i Rating by Derek Archila at Oppenheimer Holdings Inc.
1/28/2017	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
1/27/2017	HC Wainwright	Set Price Target	Buy	$18.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
1/26/2017	BTIG Research	Reiterated Rating	Positive	$11.00	N/A	i
1/21/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
1/21/2017	Oppenheimer	Set Price Target	Buy	$10.00	N/A	i Rating by Derek Archila at Oppenheimer Holdings Inc.
1/20/2017	BTIG Research	Reiterated Rating	Buy	$11.00	N/A	i
1/20/2017	Rodman & Renshaw	Boost Price Target	Buy	$17.00 ➝ $18.00	N/A	i
1/4/2017	Oppenheimer	Initiated Coverage	Outperform	$10.00	N/A	i
12/31/2016	Rodman & Renshaw	Boost Price Target	Buy	$16.00 ➝ $17.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
12/23/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
12/23/2016	Rodman & Renshaw	Boost Price Target	Buy	$16.00 ➝ $17.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
12/23/2016	BTIG Research	Reiterated Rating	Buy	$11.00	N/A	i
12/15/2016	Roth Capital	Reiterated Rating	Buy	$6.50	N/A	i
12/13/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00 ➝ $16.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
12/12/2016	HC Wainwright	Set Price Target	Buy	$16.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
12/9/2016	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
12/6/2016	BTIG Research	Reiterated Rating	Buy	$11.00	N/A	i
11/30/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
11/14/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
11/11/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
10/24/2016	HC Wainwright	Set Price Target	Buy	$15.00	N/A	i Rating by Ram Selvaraju at HC Wainwright
10/21/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
10/17/2016	BTIG Research	Reiterated Rating	Positive	$11.00	N/A	i
9/16/2016	BTIG Research	Reiterated Rating	Buy	$11.00	N/A	i Rating by Tim Chiang at BTIG Research
9/8/2016	HC Wainwright	Set Price Target	Buy	$15.00	N/A	i Rating by ram selvaraju at HC Wainwright
9/8/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
8/25/2016	BTIG Research	Initiated Coverage	Buy	$11.00	N/A	i Rating by Tim Chiang at BTIG Research
8/13/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
7/19/2016	BTIG Research	Reiterated Rating	Buy	$11.00	N/A	i Rating by Tim Chiang at BTIG Research
7/17/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A	i Rating by John Newman at Canaccord Genuity
7/12/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
5/26/2016	Roth Capital	Reiterated Rating	Buy	$6.50	N/A	i Rating by Michael Higgins at Roth Capital
5/23/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw
5/23/2016	BTIG Research	Reiterated Rating	Buy	$11.00	N/A	i Rating by Tim Chiang at BTIG Research
5/23/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A	i
5/9/2016	Roth Capital	Reiterated Rating	Buy		N/A	i Rating by Michael Higgins at Roth Capital
5/9/2016	Rodman & Renshaw	Lower Price Target	Buy	$16.00 ➝ $15.00	N/A	i Rating by Ram Selvaraju at Rodman & Renshaw

(Data available from 5/8/2016 forward)

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Today's Range

Now: N/A

50 Day Range

MA: $0.02

$0.01

$0.03

52 Week Range

Now: N/A

Volume

N/A

Average Volume

6,081,307 shs

Market Capitalization

$7.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Synergy Pharmaceuticals?

The following equities research analysts have issued research reports on Synergy Pharmaceuticals in the last twelve months:
View the latest analyst ratings for SGYP.

What is the current price target for Synergy Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Synergy Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Synergy Pharmaceuticals in the next year.
View the latest price targets for SGYP.

What is the current consensus analyst rating for Synergy Pharmaceuticals?

Synergy Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SGYP.

What other companies compete with Synergy Pharmaceuticals?

Other companies that are similar to Synergy Pharmaceuticals include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Incyte, Exact Sciences, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Novavax, Repligen, United Therapeutics and Neurocrine Biosciences.

How do I contact Synergy Pharmaceuticals' investor relations team?

Synergy Pharmaceuticals' physical mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company's listed phone number is 212-297-0020 and its investor relations email address is [email protected] The official website for Synergy Pharmaceuticals is www.synergypharma.com.